• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Evotec AG (FSE: EVT, TecDAX)

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. *

 

	Start	2005-06-24 renamed
	Group	Evotec (Group)
	Predecessor	Evotec OAI AG
	Industry	drug discovery technology
	Industry 2	drug discovery services
	Person	Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
	Person 2	Spillner, Enno (Evotec 201607– CFO before 4SC CEO + CFO before BioM Venture Capital GmbH)
	Region	Hamburg
	Country	Germany
	Street	7 Essener Bogen
	City	22419 Hamburg
	Tel	+49-40-56081-0
		Address record changed: 2018-07-24
Basic data	Employees	F: 1,001 to 5,000 (2017-12-31)
	Currency	EUR
	Annual sales	257,630,000 (revenues, consolidated (2017) 2017-12-31)
	Profit	23,999,000 (2017-12-31)
	Cash	67,017,000 (2017-12-31)
		* Document for �About Section�: Evotec AG. (5/31/18). "Press Release: Evotec Forms Academic Bridge »LAB591« with Arix Bioscience and Fred Hutchinson Cancer Research Center". Hamburg.
		Record changed: 2018-12-04

Advertisement

More documents for Evotec (Group)

• [1] Evotec AG. (12/4/18). "Press Release: Evotec and Leo Pharma Form Drug Discovery Alliance Targeting Dermatological Conditions". Hamburg & Ballerup....
• [2] Evotec AG. (11/21/18). "Press Release: Evotec and Immuneering to Collaborate on Artifical Intelligence (“AI”) Driven Ligand Identification for Rare Hereditary Metabolic Diseases". Hamburg & Cambridge, MA....
• [3] Evotec AG. (11/13/18). "Press Release: Evotec AG Reports First Nine-months 2018 Results and Corporate Updates". Hamburg....
• [4] Evotec AG. (10/11/18). "Press Release: Evotec and Celgene Expand iPSC Collaboration to Include additional Cell Lines. $6M Payment to Access additional Cell Lines". Hamburg....
• [5] Evotec AG. (10/4/18). "Press Release: LAB150 Awards Its Second Drug Discovery Project from Canada’s Largest Research-based Hospital, The University Health Network (UHN)". Toronto....
• [6] Evotec AG. (10/4/18). "Press Release: Evotec Signs Agreement with Sanofi to Advance Early Stage Academic Research into Novel Therapeutic Candidates". Hamburg....
• [7] Evotec AG. (9/17/18). "Press Release: Evotec and Almirall Enter into Research Collaboration in the Field of Dermatiological Diseases". Hamburg & Barcelona....
• [8] Evotec AG. (9/6/18). "Press Release: Evotec AG Listed in MDAX". Hamburg....
• [9] Evotec AG. (9/6/18). "Press Release: Evotec and Celgene Enter Partnership in the Field of Targeted Protein Degradation". Hamburg....
• [10] Evotec AG. (9/3/18). "Press Release: Evotec to Attend Upcoming Investor Conferences". Hamburg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2018. Made in Germany.